Definium Therapeutics
DFTX
35.09
-0.53
-1.49%
Definium Therapeutics
US · DFTX
#2132 by market cap
Listed 1970
35.09
-0.53
-1.49%
Live - 5344 symbols - heartbeat 178s ago
· 2026-10-08 07:26
Pre-market
34.74
-1.00%
After-hours
35.07
-0.06%
Overnight
35.86
+2.19%
- Market cap
- 4.71B
- P/E (TTM)i
- -10.23
- P/Bi
- 5.13
- EPSi
- -2.06
- Div yieldi
- 0.00%
- 52W posi
- 63%
Reader sentiment
Are you bullish or bearish on DFTX?
Anonymous reader poll. Unscientific, not investment advice.
About Definium Therapeutics
Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.
- Founded
- 2010
- CEO
- Mr. Robert B. Barrow
- Employees
- 106
- Headquarters
- New York, New York, United States of America
- Fiscal year end
- 12-31
- Website
- definiumtx.com
Company profile
- Exchange
- US
- Symbol
- DFTX
- Market-cap rank
- #2132
- Listing date
- 1970-01-01
- Market cap
- 4.71B
- Float cap
- 4.39B
- Shares out
- 134.37M
- Float shares
- 125.17M
Sectors & themes
Biotechnology
Quote time 2026-10-08 07:26:40 · For reference only, not investment advice and not tailored to your situation.